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1069-116 Prevalence and Importance of Renal Dysfunction in 
Hospitalized Heart Failure Patients
Colin Berry, John McMurray, University of Glasgow, Glasgow, United Kingdom
Background: Renal dysfunction is an adverse prognostic marker in heart failure (HF).
Although serum creatinine concentration is the usual method for assessing renal dys-
function, the accuracy of this test in HF is uncertain. Consequently, the true prevalence of
renal dysfunction in unselected HF patients is unknown.
Methods: Index emergency admissions with HF to one University hospital during the year
2000 were studied. Hematological and biochemical (from the initial blood samples taken
on the day of admission) data were obtained from hospital electronic records.
Results: 528 consecutive, first-admissions, with HF were included in this study. The
median follow-up was 693 days (range 1 - 978 days). Mean serum creatinine (standard
deviation [SD]) concentration on admission was 1.5(0.9) mg/dL and 51% of patients had
an elevated creatinine (>1.3 mg/dL) concentration. Glomerular filtration rate (GFR) was
calculated using the Modified Diet in Renal Disease equation. Mean GFR was 51(22)
mL/min/1.73m2. Mean GFR of men was greater than that of women (56(23) vs 48(20);
P=0.0001). 436(96%) patients had a reduced GFR (<90 mL/min/1.73m2 ). 66%, 16%,
and 3% had a GFR less than 60, 30 and 15 mL/min/1.73m2, respectively. 199/219 (90%)
of patients with a normal creatinine had a low GFR. On multiple regression analysis, age
(coefficient of variation [95% confidence interval]; -0.6 (-0.7, -0.4); P<0.0001), male sex
(11 (6,16); P<0.0001), ACE inhibitor therapy (6.1(0.9, 11); P=0.02), Hb (1.6(0.4, 2.8) and
plasma CRP (0.6(-0.1,-0.02) were independent predictors of GFR.
On Cox survival analysis, GFR (SD) was an independent predictor of mortality (odds
ratio [95% confidence interval] 0.89 [0.78,1.0]; P<0.08), HF readmission (0.8 [0.6,1.1;
P=0.02] and death or HF readmission (0.8 [0.7,1.0]; P=0.03).
CONCLUSIONS: Measurement of serum creatinine fails to detect impaired renal function
in a high proportion of hospitalized HF patients. Normal renal function on admission is
rare in these patients, and GFR is an independent predictor of long-term outcomes. In
addition to established predictors of renal function, we found that ACE-I therapy and
plasma CRP concentrations are also predictors.
1069-117 Prognostic Impact of Catabolic/Anabolic Imbalance in 
Chronic Heart Failure 
Darlington O. Okonko, Martino Crosato, Wolfram Steinborn, Stephan von Haehling, 
Mariantonietta Cicoira, Wolfram Doehner, Paul R. Kalra, Phillip A. Poole-Wilson, Stefan 
D. Anker, Imperial College, National Heart and Lung, London, United Kingdom, Applied 
Cachexia Research, Charité, Virchow-Klinikum, Berlin, Germany
Background: Chronic heart failure (CHF) is characterised by a catabolic/anabolic imbal-
ance. The cortisol/DHEA ratio (CDR) reflects this disequilibrium. Its prognostic utility is
unknown.
Method & Results: Survival and CDR were analysed in 102 stable male CHF patients
(age 62±11y, NYHA class 2.6±0.7, CDR 50±5, urate 468±136 µmol/L, creatinine 124±43
µmol/L, body mass index 26.1±4.4 kg/m2, left ventricular ejection fraction 26±11 %, peak
oxygen consumption(VO2) 18.1±5.8 mL/kg/min, ventilation/carbon dioxide production
slope (VE/VCO2) 38±13). During follow-up (55±40 months, all survivors:>16 months), 48
patients died (12-month mortality 15%, at 36 months: 38%). In univariant Cox analysis
only CDR, urate, creatinine, NYHA, VE/VCO2, peak VO2, age (all p<0.01) and body
mass index (p=0.03) predicted survival. In bivariant models CDR was universally inde-
pendently predictive of survival. Urate, NYHA, VE/VCO2 and peak VO2 predicted sur-
vival, independently of CDR. In multivariant analysis, CDR(p<0.0001), urate (p=0.008),
NYHA class (p=0.002), VE/VCO2 (p=0.04) but not peak VO2 (p>0.2) were independent
prognosticators. We subdivided patients by CDR quartiles (Q, see figure). Survival at 36
months for patients in Q1, Q2, Q3 and Q4 was 92, 81, 67 and 35% respectively.
Conclusion: Catabolic/anabolic imbalance(quantified by the cortisol/DHEA ratio) inde-
pendently predicts survival in CHF. Therapeutic strategies blunting catabolism and/or
augmenting anabolism may confer prognostic benefits in CHF. 
1069-118 Frequency Distribution of Hospitalized Heart Failure 
Patients: Data From the Adjudication Committee of Val-
HeFT
Peter E. Carson, Ileana L. Pina, Cristina Opasich, Christopher O'Connor, Felix Tristani, 
Lynne Warner Stevenson, Allen Hester, Nancy Feliciano, Nora Aknay, Veteran Affairs 
Medical Center, Washington DC, DC
Background: Categorization of hospitalization data, particularly by adjudication commit-
tees, has been rare in heart failure (HF) trials which have commonly targeted HF
events.In ValHeFT, we examined the adjudicated hospitalization database, 49.7% of
admissions, to categorize non HF hospitalizations.
Methods: The independent endpoints committee (EC) of Val-HeFT adjudicated every
non-elective hospitalization up to and including the first of each primary event. All hospi-
talizations were categorized as HF or non-HF (and cardiovascular (CV) or non-CV). For
CV/non CV, body systems were classified using the MEDDRA dictionary if an EC assign-
ment was not made. Multiple hospitalizations occurred for some patients.
Results: For 5010 patients randomized, 5962 hospitalizations were investigator-
assessed for 2509 patients, and 2962 hospitalizations were EC-adjudicated for 1834
patients. Of the patients with adjudicated hospitalizations, 83.0% (1522) had at least one
hospitalization classified as CV-related, approximately 34% (618) as non-CV, 44.3%
(812) as HF-related, and 71.8% (1316) as non-HF (including CV-related). Among CV rea-
sons other than HF, unstable angina (249, 13.6%) and invasive cardiac procedures (159,
8.7%) were common, while myocardial infarction (MI) (59, 3.2%) and stroke (51, 2.8%)
were not. Leading non-CV causes were infection (197, 10.7%), general disorders (e.g.,
chest pain NEC, malaise) (136, 7.4%), and pulmonary (83, 4.5%). Among the 812
patients with HF hospitalizations, 718 (88.4%) met criteria by IV use or oral medication
addition, 87 (10.7%) with pulmonary edema, and 16 (2.0%) with shock.
Conclusion: Non-HF hospitalizations appear commonly in HF patients. Among non HF
CV admissions, unstable angina and invasive cardiac procedures were common and irre-
versible CV endpoints (MI and stroke) were infrequent. Future HF trials may consider
those proportions of hospitalizations in designing composite endpoints and in further
assessing the importance of non-HF morbidity in the disease.
1069-119 Predictors of Mortality in Patients Hospitalized With 
Worsening Heart Failure: Insights From the ACTIV in 
CHF Trial
Christopher M. O'Connor, Kirkwood F. Adams, Jr., Wendy A. Gattis, Alejandro 
Barbagelata, Uri Elkayam, Frank Mc Grew, Jalal Ghali, Raymond Benza, Marc Klapholz, 
John Ouyang, Cesare Orlandi, Mihai Gheorghiade, Northwestern University Feinberg 
School of Medicine, Chicago, IL
Background: Patients hospitalized for worsening heart failure have a high post-dis-
charge mortality and readmission rate. Limited information, however, exists for risk strati-
fication in this population.
Methods: The Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in
Chronic Heart Failure (ACTIV in CHF) trial randomized 319 patients admitted to the hos-
pital for worsening heart failure to tolvaptan or placebo, in addition to standard therapy.
Cox proportional hazards analysis was used to explore the relation between baseline
characteristics and mortality within 60-day post-discharge, adjusted for treatment. Base-
line variables examined included demographics, history, renal function, and clinical labo-
ratory values. 
Results: The overall unadjusted 60-day mortality was 5.8% and the 60-day mortality/re-
hospitalization rate was 26.7%. The two most important baseline independent predictors
of mortality were elevated BUN (BUN > 29 mg/dL; HR = 5.54, 95% CI 2.17 - 14.17, p <
0.0004) and hyponatremia (serum Na < 136 mEq/L; HR = 3.12, 95% CI 1.47 - 6.61, p <
0.003). Anemia (Hemoglobin < 13 for men and < 12 for women; HR 1.59; 95% CI 0.72 -
3.52, p = 0.26) and low systolic blood pressure (systolic blood pressure < 90 mm Hg; HR
= 1.94, 95% CI 0.49 - 7.68, p = 0.34), trended toward statistical significance.
Conclusions: In patients discharged after hospitalization for worsening heart failure, ele-
vated BUN and hyponatremia are strong predictors of 60-day mortality. Clinical decision-
making processes and further research efforts should target these two factors.
